Posted by Michael Wonder on 18 Jul 2017
EU regulators charge Teva over pay-for-delay drug deal
17 July 2017 - EU antitrust regulators charged Israeli drugmaker Teva on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.
The crackdown by the European Commission follows fines against scores of companies including Denmark's Lundbeck, U.S. giant Johnson & Johnson and France's Servier in recent years over similar deals.
The EU competition enforcer's 2009 inquiry into the sector showed that so-called pay-for-delay deals cost European consumers billions of euros.
